Light Chain Bioscience | Novimmune SA

Biotechnology ResearchSwitzerland51-200 Employees

NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019.

NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as:

“Light Chain Bioscience – A brand of Novimmune SA”.

The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function.

A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop.

Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. 

In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.

Sign up for free to view info

Email Format Employee directory